ARKG vs XBI

Key Takeaways

• ARKG is an actively managed thematic ETF focused on the genomics revolution, while XBI passively tracks a modified equal-weighted biotechnology index.
• ARK Genomic Revolution ETF (ARKG) maintains a concentrated portfolio of approximately 30–40 holdings with top positions often exceeding 5–9%, whereas SPDR S&P Biotech ETF (XBI) holds roughly 140–160 stocks with individual weights typically under 2%.
• ARKG carries a higher expense ratio of 0.75% compared to XBI’s 0.35%, reflecting its active management approach versus XBI’s passive structure.
• Both ETFs target the biotechnology sector but differ in exposure: ARKG emphasizes innovative genomics companies across healthcare and related fields, while XBI provides broader diversification within U.S. biotechnology firms.
• XBI’s equal-weighted methodology reduces concentration risk relative to ARKG’s active selection, though both exhibit elevated volatility typical of the biotech sector.
• Structural differences in management style, cost, and diversification position the two ETFs as complementary rather than direct substitutes for investors seeking biotech or genomics exposure.

Introduction

ARK Genomic Revolution ETF (ARKG) and SPDR S&P Biotech ETF (XBI) both provide exposure to the biotechnology sector, making them relevant for investors interested in healthcare innovation and genomics advancements. ARKG pursues an active thematic strategy centered on the genomics revolution, while XBI offers passive, rules-based exposure to a broad basket of biotech companies. These ETFs do not compete directly but represent alternative strategies targeting similar investor goals of capital growth within the life sciences space.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed ETF that seeks long-term growth of capital by investing primarily in equity securities of companies relevant to the genomics revolution. The fund typically holds 30–40 securities and maintains a non-diversified structure. Top holdings as of recent data include TXG, TWST, TEM, CRSP, and PSNL, with individual weights frequently in the 5–10% range. Sector allocations concentrate in healthcare, with additional exposure to information technology and related fields. The expense ratio stands at 0.75%. ARKG employs active rebalancing based on ARK Invest’s research-driven approach to disruptive innovation in genomics.

SPDR S&P Biotech ETF (XBI) Overview

SPDR S&P Biotech ETF (XBI) is a passively managed ETF that seeks to provide investment results corresponding to the performance of the S&P Biotechnology Select Industry Index, a modified equal-weighted index representing the biotechnology segment of the S&P Total Market Index. The fund typically holds 140–160 securities. Top holdings generally include companies such as MRNA, TWST, and various smaller biotech firms, each typically weighted around 1–2%. Sector allocations are overwhelmingly in healthcare, specifically biotechnology. The expense ratio is 0.35%. XBI uses rules-based rebalancing to maintain equal weighting within the index methodology, promoting broad diversification across market capitalizations.

Industry and Thematic Backdrop

The biotechnology sector continues to benefit from ongoing innovation in gene editing, precision medicine, and artificial intelligence applications in drug discovery. Macroeconomic drivers include interest rate expectations, which influence growth-oriented biotech valuations, and regulatory developments around FDA approvals and clinical trial pathways. Capital flows into the sector have shown resilience amid merger and acquisition activity, though risks persist from clinical setbacks, patent expirations, and broader economic sensitivity affecting smaller-cap companies. Both ETFs operate within this environment of high innovation potential tempered by elevated sector volatility.

Performance and Positioning Comparison

In recent market cycles, ARKG’s active thematic focus has led to periods of outperformance during genomics breakthroughs but also sharper drawdowns due to concentration in smaller, higher-risk holdings. XBI’s equal-weighted approach has provided more balanced participation across the biotech landscape, often resulting in relatively lower volatility compared to concentrated active strategies during sector rotations. Performance differences tie to earnings cycles of top holdings, shifts in investor preference between growth and value within healthcare, and macroeconomic factors such as interest rate movements. Relative positioning favors XBI for investors seeking diversified biotech exposure and ARKG for those targeting specific genomics themes.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover opportunities aligned with your strategy.

Tickeron AI Verdict

Based on observable factors such as structural strength, cost efficiency, and diversification profile, Tickeron’s AI would currently assign a higher probability of favor to SPDR S&P Biotech ETF (XBI). The lower expense ratio, broader holdings, and rules-based equal-weighting provide a more consistent risk-adjusted framework within the volatile biotech sector compared to the higher-cost, concentrated active approach of ARK Genomic Revolution ETF (ARKG).

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations